| (Values in U.S. Thousands) | Dec, 2017 | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 |
| Sales | 1,070 | 1,070 | 870 | 0 | 0 |
| Sales Growth | unch | +22.99% | unch | unch | unch |
| Net Income | -23,210 | -25,870 | -24,970 | -19,040 | -7,850 |
| Net Income Growth | +10.28% | -3.60% | -31.15% | -142.55% | unch |
Steadymed Ltd Ord Sh (STDY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
SteadyMed Ltd. is a specialty pharmaceutical company which focused on the development of drug products to treat orphan and other diseases. The company's lead candidate consist of Trevyent(R), a development stage drug product which utilizes SteadyMed's PatchPump(R) technology to treat pulmonary arterial hypertension. SteadyMed Ltd. is headquartered in San Ramon, California.
Fiscal Year End Date: 12/31